Business Wire

World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London

Jaa

The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/

Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science  ...

Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire)

The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based processes that show results in patient safety – and for developing new APSS. These sessions provide healthcare professionals, advocates, and enthusiasts the opportunity to contribute their experiences and expertise, which is critical to process improvement, while also promoting transparency and encouraging aligned incentives that will eventually lead to ZERO preventable patient deaths in hospitals by 2020.

The World Patient Safety, Science & Technology Summit, and Breakout Sessions are supported by the Rt. Hon Jeremy Hunt, MP, Secretary of State for Health and Social Care, Department of Health United Kingdom and co-convened by the European Society of Anaesthesiology. This year’s breakout sessions will include:

Session I

Vaccine Safety

Many healthcare institutions can improve patient safety through procedures related to immunization, safety monitoring, and pertinent participatory information systems. This session will exchange the latest advances in patient and vaccine safety research methods, and pertinent key performance indicators for healthcare institutions. Finally, the group will crystallize the plans for developing an Actionable Patient Safety Solutions (APSS) that focuses on safeguarding patients through engagement, protecting the providers caring for patients, and shielding at-risk patients. Other key topics of discussion will include systematic monitoring of adverse events and feedback knowledge updates for healthcare providers.

Person and Family Engagement (PFE)

Person and Family Engagement is an underused “natural resource” for improving patient safety. Ample evidence has accumulated which demonstrates that when patients are actively engaged partners, they achieve better outcomes and help produce innovative solutions. Persons who use care or manage its use for loved ones are highly motivated to partner with professional and organizational care providers to drive change across the care continuum. Their experiences bring an urgency to the patient safety movement that propels action by generating empathy – they engage our hearts as well as our minds and hands.

Falls

Injuries related to falls impose a catastrophic cost of care on families and healthcare economics. Fall prevention and injury reduction require a collaborative approach involving leadership, clinical intervention, and patent and family partnership. This session will explore the Actionable Patient Safety Solutions for Fall Prevention and Injury Reduction. The latest research and science will be discussed along with revisions to the APSS that can assist in care that reduces harm, injury, and death.

Driving Sustainable Change in Hand Hygiene - The Problem We Only THINK We Solved

If hand hygiene is the most effective way to prevent avoidable HAIs, why is global compliance below 50%? Recent studies prove that three elements are essential for sustainable improvement: Accurate measurement, evidence-based feedback, and top-down accountability. The current hand hygiene APSS incorporates this learning into actionable guidelines. Attendees will learn how to translate emerging science into action by providing input into the APSS through sharing experience & knowledge.

Session II

Reducing Unnecessary C-Sections

One of the life-altering procedures of modern obstetrics is the performance of an appropriately timed and executed cesarean delivery and yet over performance can lead to short and long-term complications and maternal deaths. In parts of the world increased cesarean section rates are associated with rising maternal mortality rates. Therefore, the avoidance of performing unnecessary cesarean births has become an important long-term strategy in reducing maternal mortality.

Sepsis

Sepsis is a growing issue worldwide. This session will review and discuss the latest APSS #9A: Early Detection & Treatment of Sepsis for High-income Countries and the new APSS #9B: Early Detection & Treatment of Sepsis for Low and Middle-income Countries. Participants will share ideas and make suggestions to improve the APSS based on their knowledge and experience. The goal of the working group session is to facilitate revisions that increase APSS effectiveness and identify ways to disseminate APSSs more widely.

Drug Shortages

Should drug shortages be viewed as a patient safety issue? That is one of the issues the working group will tackle in this session. Pharmaceutical shortages have a profound effect on clinical practice and patient outcomes and increase health care costs. The objectives of the session are to understand the reasons for drug shortages and define alternatives for shortage prevention and mitigation. Participants will also discuss the role of technology in coming up with solutions.

For more information on the breakout sessions, or to register, please visit http://www.cvent.com/events/6th-annual-world-patient-safety-science-technology-summit/event-summary-354a3027b4904b42940fda0fc321463f.aspx.

About Patient Safety Movement Foundation:

More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

Contact information

Patient Safety Movement Foundation
Tanya Lyon, (949) 351-2858
tanya.lyon@patientsafetymovement.org

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EETTiedote

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EETTiedote

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EETTiedote

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EETTiedote

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EETTiedote

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin

Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EETTiedote

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme